Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | 623 hari yang lalu
Stocktwits
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Teg: REGN
Stocktwits
read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 442 hari yang lalu
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 476 hari yang lalu
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 1204 hari yang lalu
Bay Street Headed For Weak Start

Bay Street Headed For Weak Start

Lower Canadian and U.S. futures amid worries about the health of US regional banks, and lingering concerns about U.S.-China trade tensions point to a weak start for the Canadian market on Friday.
RTTNews | 32 minit yang lalu
FTSE 100 Down 1.4%; Bank Stocks Fall On U.S. Lenders' Credit Woes

FTSE 100 Down 1.4%; Bank Stocks Fall On U.S. Lenders' Credit Woes

The UK market is down sharply on Friday, hurt by a sell-off in the financials sector amid concerns about the health of U.S. banks after a couple of regional banks disclosed that they were exposed to alleged fraud by borrowers, spreading jitters about credit market turmoil.
RTTNews | 1j 53min yang lalu
Pound Falls Amid BoE Rate Cut Speculation

Pound Falls Amid BoE Rate Cut Speculation

The British pound weakened against other major currencies in the European session on Friday, amid rising expectations that the Bank of England (BoE) will cut interest rates further this year.
RTTNews | 2j 32min yang lalu
Alat
Kalendar Ekonomi
Waktu pasaran
Kadar faedah
Kalendar cuti
Pasaran Forex
Volatiliti Forex
Korelasi Forex
Berita Forex
Analisis Forex
Data COT
Kecairan
Kalkulator Forex
Peta Panas Forex
Petunjuk ekonomi
Komuniti
Komuniti
Sistem
Sistem Paling Popular
Strategi
Peraduan
Carta Forex
Sentimen Forex
Petunjuk Outlook
Ulasan
Broker
Firma Dagangan Proprietari
Perkhidmatan VPS
Penyedia Isyarat
Perkhidmatan Pengaturcaraan EA
Program Afiliasi
Perkhidmatan PAMM Broker
Perkhidmatan Program Rebat
Platform Dagangan
Penasihat Pakar
Pertukaran Kripto
Kursus dagangan
Broker
Spreads Forex
Sebut Harga Forex Broker
Pertukaran Broker Forex
Jumlah Broker Forex
Promosi Broker Forex
Siaran Akhbar
Platform
Widget
Ciri-ciri
API
RSS
Stock Portfolio
Affiliate Software
Carta Lanjutan
Sokongan
Soalan Lazim
Bantuan
Hubungi Kami
Laporkan pepijat!
Mengenai
Blog
&salin; 2025 Myfxbook Ltd. Hak Cipta Terpelihara.
PERINGATAN RISIKO TINGGI: Perdagangan pertukaran mata wang asing mempunyai risiko tinggi yang mungkin tidak sesuai untuk semua jenis pelabur. Leveraj menimbulkan risiko dan kerugian tambahan. Sebelum anda memutuskan untuk berdagang pertukaran mata wang asing, pertimbangkan dengan teliti objektif pelaburan, tahap pengalaman dan toleransi risiko anda. Anda berkemungkinan kehilangan sebahagian atau semua pelaburan awal anda. Jangan melaburkan wang yang anda tidak mampu untuk kehilangan. Didik diri anda tentang risiko yang berkaitan dengan perdagangan pertukaran asing, dan dapatkan nasihat daripada penasihat bebas kewangan atau cukai jika anda mempunyai sebarang pertanyaan mengenainya. Semua data dan maklumat yang disediakan adalah semata-mata untuk tujuan maklumat, dan bukan bertujuan untuk tujuan perdagangan atau nasihat. Prestasi masa lalu tidak semestinya menunjukkan hasil masa depan.